& publish your company news

RadioMedix Raised $40 million Series A Financing

Proceeds will be used to develop RadioMedix's flagship radiopharmaceutical AlphaMedixTM.


RadioMedix, Inc

RadioMedix, Inc., a clinical-stage biotechnology business, announced a $40 million Series A funding round deal with an entity affiliated to Portland Investment Counsel Inc. RadioMedix is dedicated to developing a pipeline of targeted alpha treatment (TAT) and diagnostic companion radiopharmaceuticals for uncommon and aggressive tumors.

The financing proceeds will be used to develop RadioMedix’s flagship radiopharmaceutical AlphaMedixTM, a lead-212 (Pb212) labelled somatostatin analogue TAT agent for the treatment of metastatic or inoperable somatostatin-expressing neuroendocrine tumors, as well as other diagnostic and therapeutic (theranostic) radiopharmaceuticals under development by the Company to address oncology needs.

RadioMedix, Inc., based in Houston and Humble, Texas, is a clinical-stage biotechnology company. The company is focused on developing novel targeted radiopharmaceuticals for cancer diagnosis, monitoring, and treatment. RadioMedix is a company that creates radiopharmaceuticals for PET imaging and therapy (alpha- and beta-labelled agents). The US FDA authorized the company’s first diagnostic product, 64Cu-DOTATATE (Detectnet®), in September 2020.

Mr. Michael Lee-Chin will be appointed to RadioMedix’s board of directors. Mr. Lee-Chin is Portland’s founder, CEO, and Executive Chairman. He has over 40 years of investment experience and a solid track record in the sector.

Related Stories

News Stories



Follow for tech world news

*This is our contributors content, you can also contribute to us by submitting your article

Discover more from Silicon Valley Journals

Subscribe now to keep reading and get access to the full archive.

Continue Reading